Bristol-Myers Squibb Company

02/16/2025 | Press release | Distributed by Public on 02/16/2025 05:59

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis